SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (71)12/10/2001 4:51:01 PM
From: Edscharp  Read Replies (1) of 75
 
Tex,

I checked BTRN's news.

I hate to be overly cynical, but BTRN sounds exactly like the early trial stuff that came out about Xoma.

I certainly agree that the early results look promising, but what next? I imagine you will be waiting another 6-10 months before they even announce the commencement of P3 trials. And then, once they start, another 6 - 10 months before completion and evaluation and then another few months or more before they file for final FDA approval and then the FDA will ruminate another 6 - 10 months before they approve it, if they approve it.

In the meantime your invested money has green mold growing on it and unless you get spectacular P3 results the stock price won't necessarily be much beyond where it is now.

But, I will place BTRN on my watch list. It is an interesting company.

Regards, Ed
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News